This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Radius Health Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

28.6%

Groei van de winst

30.1%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	35.3%
Rendement op eigen vermogen	n/a
Nettomarge	-30.7%
Laatste winstupdate	30 Jun 2022

Recente prestatie-updates uit het verleden

Recent updates

Radius Recycling Stays In The Scrap Pile

Jul 16

Radius Recycling: An Attractive, But Volatile, Play On A Cleaner Future

Jun 03

Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype

Aug 11

How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?

Jan 01

Radius Health on-track for record quarterly revenue for TYMLOS-SC

Dec 15

Opbrengsten en kosten

Hoe Radius Health geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGM:RDUS Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 22	223	-69	129	121
31 Mar 22	217	-73	127	122
31 Dec 21	230	-70	130	131
30 Sep 21	228	-76	138	128
30 Jun 21	249	-60	134	134
31 Mar 21	247	-87	140	151
31 Dec 20	239	-109	143	159
30 Sep 20	232	-113	144	158
30 Jun 20	200	-136	148	149
31 Mar 20	191	-128	150	131
31 Dec 19	173	-133	155	115
30 Sep 19	152	-149	163	104
30 Jun 19	133	-169	170	100
31 Mar 19	115	-203	179	99
31 Dec 18	99	-221	186	98
30 Sep 18	72	-251	193	97
30 Jun 18	58	-259	197	91
31 Mar 18	37	-259	199	84
31 Dec 17	22	-254	189	81
30 Sep 17	14	-236	167	82
30 Jun 17	1	-224	138	89
31 Mar 17	0	-199	104	97
31 Dec 16	0	-183	80	105
30 Sep 16	0	-163	62	104
30 Jun 16	0	-145	51	95
31 Mar 16	0	-125	40	84
31 Dec 15	0	-102	31	68

Kwaliteitswinsten: RDUS is currently unprofitable.

Groeiende winstmarge: RDUS is currently unprofitable.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: RDUS is unprofitable, but has reduced losses over the past 5 years at a rate of 28.6% per year.

Versnelling van de groei: Unable to compare RDUS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: RDUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).

Rendement op eigen vermogen

Hoge ROE: RDUS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

This company listing is no longer active

Radius Health Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Radius Health, Inc. to Report Q1, 2022 Results on May 05, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Third quarter 2021 earnings released: US$0.47 loss per share (vs US$0.14 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.94 loss in 2Q 2020)

Recent updates

Radius Recycling Stays In The Scrap Pile

Radius Recycling: An Attractive, But Volatile, Play On A Cleaner Future

Radius to Be Delisted from the NASDAQ Global Market

Patient Square Capital, LP and Gurnet Point Capital Limited completed the acquisition of Radius Health, Inc. (NasdaqGM:RDUS) from Repertoire Partners LP, Velan Capital Investment Management LP and others.

Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Velan-Repertoire to Withdraw Director Nominations due to Pending Sale of Radius Health

Radius Health, Inc. Announces First Patient Randomized in the Rad011 Pivotal Trial for Prader-Willi Syndrome

Price target increased to US$10.00

Patient Square Capital, LP and Gurnet Point Capital Limited entered into a definitive agreement to acquire Radius Health, Inc. (NasdaqGM:RDUS) for approximately $500 million.

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

Velan Capital Investment Responds to Radius Health’s Board

Now 24% undervalued after recent price drop

Radius Health, Inc., Annual General Meeting, Jul 08, 2022

Menarini Group and Radius Health, Inc. Present A Subgroup Analysis from the Elacestrant Pivotal Phase 3 EMERALD Clinical Trial At the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Radius Health, Inc. Provides Update on Abaloparatide Transdermal System

Velan LP Provides Information to Shareholders of Radius Health Inc

Radius Health, Inc. Appoints Jennifer A. Jarrett and Susan Vissers Lisa to Board of Directors

Consensus forecasts updated

Radius Health, Inc. Provides Earnings Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Forecast breakeven date moved forward to 2022

Consensus forecasts updated

Radius Health, Inc. to Report Q1, 2022 Results on May 05, 2022

Consensus forecasts updated

Consensus forecasts updated

Velan Capital Engages in Discussions with Radius Health

Radius Health Files Supplemental New Drug Application with the Food and Drug Administration for TYMLOS in Men with Osteoporosis

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date moved forward to 2022

Reevaluating Radius Health

Forecast breakeven date pushed back to 2023

Radius Announces Update on TYMLOS® (abaloparatide) Label

Radius Health, Inc. Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal System in Postmenopausal Women with Osteoporosis

Price target decreased to US$20.50

Forecast breakeven date pushed back to 2023

Third quarter 2021 earnings released: US$0.47 loss per share (vs US$0.14 loss in 3Q 2020)

Price target increased to US$23.86

CFO, VP, Treasurer, Principal Finance Officer & Principal Accounting Officer James Chopas has left the company

Price target decreased to US$22.29

Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.94 loss in 2Q 2020)

Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study

Consensus forecasts updated

Consensus forecasts updated

Radius Health, Inc. Reiterates Revenue Guidance for the Full Year of Fiscal 2021

First quarter 2021 earnings released: US$0.34 loss per share (vs US$0.81 loss in 1Q 2020)

Radius Health EPS misses by $0.02, misses on revenue

Consensus forecasts updated

Analysts update estimates

Full year 2020 earnings released: US$2.35 loss per share (vs US$2.89 loss in FY 2019)

Revenue beats expectations

When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?

Radius Health, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: US$22.94

Revisiting Radius Health

Price target raised to US$22.00

New 90-day high: US$21.60

Radius Health, Inc. Announces Commercial Agreement with Paladin Labs for Abaloparatide in Canada

Radius Health acquires global rights to RAD011 in Prader-Willi syndrome

Radius Health, Inc. Announces Board Changes

How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?

Radius Health, Inc. Hires Peter Been as Executive Director and Head of Clinical Development for the Abaloparatide Program

New 90-day high: US$18.54

Radius Health on-track for record quarterly revenue for TYMLOS-SC

New 90-day high: US$14.86

Revenue and earnings miss expectations

Third quarter 2020 earnings released: US$0.14 loss per share

New 90-day high: US$13.88